SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (10.9), the stock would be worth HK$1.35 (99% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 854.7 | HK$106 |
0%
|
| 3-Year Average | 10.9 | HK$1.35 |
-99%
|
| 5-Year Average | 5.1 | HK$0.63 |
-99%
|
| Industry Average | 35.7 | HK$4.43 |
-96%
|
| Country Average | 26.4 | HK$3.27 |
-97%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
S
|
SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
|
23.6B HKD | 854.7 | -753 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 61.3 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 37.8 | 4 516.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 13.7 |
| Median | 26.4 |
| 70th Percentile | 52.8 |
| Max | 2 279 450.9 |
Other Multiples
SciClone Pharmaceuticals (Holdings) Ltd
Glance View
SciClone Pharmaceuticals (Holdings) Ltd. operates at the fascinating intersection of biotechnology and pharmaceuticals, delivering innovative solutions in the healthcare sector. With roots firmly planted in the bustling life sciences landscape of China, SciClone specializes in the development and commercialization of novel medicines that address critical health concerns, particularly in oncology, infectious diseases, and cardiovascular conditions. By leveraging a strategic blend of in-house research and development, coupled with partnerships with global biotech firms, SciClone is able to bring cutting-edge therapies to market. This blend of innovation and collaboration fuels the company’s pipeline, allowing it to introduce new medical solutions to meet the ever-growing demand for advanced healthcare in a rapidly aging population. The financial engine of SciClone revolves around its adept management of significant partnerships and distribution networks, ensuring their pharmaceutical products reach a broad base of healthcare providers and patients. Their business model is anchored in acquiring licensing rights for promising drug candidates, which they then shepherd through clinical trials and regulatory approvals. Once approved, these drugs are marketed through SciClone’s robust sales channels. This model not only diversifies their revenue streams but also mitigates risk by relying on a portfolio of products rather than a single offering. Importantly, by focusing on high-margin specialty pharmaceuticals, SciClone has positioned itself as a nimble player in the pharmaceutical landscape, with an eye toward sustainable growth and expansion in emerging markets.
